Similarly, aberrant HDAC expression in lymphoma [47] argues for the use of HDACIs in this disorder, and in fact these agents have received approval or orphan drug status in CTCL/PTCL and some forms of DLBCL [48]. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.